Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 264 of 5804
-
Experimental gene therapy aims to trick immune system to attack brain tumors
Disease control Recruiting nowThis phase I trial tests the safety, side effects and best dose of AdV-HSV1-TK and AdV-Flt3L in combination with valacyclovir for the treatment of patients with primary cancerous (malignant) brain tumors that can be removed by surgery (resectable) and that have come back after a …
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to boost survival in severe alcoholic hepatitis
Disease control Recruiting nowOnly patients suffering from a severe form of alcoholic hepatitis (Maddrey's discriminant function greater than 32) require medical treatment. Oral prednisolone for 28 days is the only treatment which has been proven to improve short-term survival over placebo in patients with se…
Phase: PHASE3 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for advanced breast cancer: phase 3 trial compares experimental combo to standard care
Disease control Recruiting nowThe purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone rece…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for tough leukemia: drug combo trial launches
Disease control Recruiting nowThis is a phase Ib/II study that aims to investigate the safety, tolerability and explore the efficacy of BCL- XL inhibition in participants with high-risk AML.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThe purpose of this study is to evaluate safety and tolerability, pharmacokinetics (PK), efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor (ARPI) or taxane-based chemotherapy. We plan to re…
Phase: PHASE1, PHASE2 • Sponsor: C Ray Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising combo aims to wipe out esophageal cancer before surgery
Disease control Recruiting nowThis study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for blood cancer patients: daily pill aims to prevent relapse without transplant
Disease control Recruiting nowThis study will explore the efficacy and safety of ivosidenib as maintenance therapy in patients with IDH1-mutated AML and high-risk MDS who are ineligible for transplantation, along with accompanying molecular biomarker research. Patients who meet the eligibility criteria will r…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug duo aims to control two cancers at once
Disease control Recruiting nowThe goal of this clinical trial is to learn if teclistamab in combination with daratumumab (Tec-Dara) works to treat newly diagnosed multiple myeloma with concurrent light chain amyloidosis (MM+AL). It will also learn about the safety of this combination. The main questions it ai…
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to stop pancreatic cancer return after surgery
Disease control Recruiting nowPancreatic cancer is a highly fatal malignant tumor. Simple surgical operations can no longer meet the treatment needs of pancreatic cancer patients. Postoperative adjuvant chemotherapy has a significant effect, which can effectively prevent or delay tumor recurrence and prolong …
Phase: PHASE3 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Robotic hands may help stroke survivors regain movement faster
Disease control CompletedThis randomized controlled trial aims to compare the effectiveness of robotic-assisted physiotherapy and conventional physiotherapy in improving hand function among patients with sub-acute stroke. Stroke often results in weakness, reduced hand strength, impaired dexterity, and di…
Phase: NA • Sponsor: Montiha Azeem • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a common antibiotic boost stroke recovery? new trial aims to find out
Disease control Recruiting nowEndovascular thrombectomy (EVT) improves outcomes in patients with acute large vessel occlusion (LVO). However, despite successful recanalization rates exceeding 80%, fewer than 50% of patients achieve favorable functional outcomes at 90 days, indicating a high rate of futile rec…
Phase: PHASE2, PHASE3 • Sponsor: Xiang Luo • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New group therapy aims to ease mental health struggles for trans teens
Symptom relief Recruiting nowThis project will study the effect of the TAG TEAM group CBT program on the mental health of trans and gender diverse adolescents. TAG TEAM was co-designed by researchers and clinicians with a group of trans and gender diverse young people to help trans and gender diverse adolesc…
Phase: NA • Sponsor: Murdoch Childrens Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Brain aneurysm showdown: which coated stent causes fewer strokes?
Disease control Recruiting nowFlow diverters (FDs) have become a mainstay of endovascular therapy for unruptured intracranial aneurysms (UIAs), yet their implantation carries an inherent risk of ischemic complications. The Pipeline Flex Embolization Device with Shield Technology (PED Shield) and the Lattice F…
Phase: NA • Sponsor: Henan Provincial People's Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a biologic drug stop lung nodules from becoming cancer?
Prevention Recruiting nowThe main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
Phase: PHASE2 • Sponsor: Robert Samstein • Aim: Prevention
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to control advanced lung cancer
Disease control Recruiting nowThis study is an open-label, multicenter, single-arm clinical study.
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo offers hope for bladder cancer patients who failed standard therapy
Disease control Recruiting nowinterventional study of intravesical chemotherapy and sistemic immunotherapy in NMIBC
Phase: PHASE2 • Sponsor: BLATAM • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug aims to cut blood transfusions for MDS patients
Disease control Recruiting nowThe main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without need…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for brain tumor patients: drug trial targets recurrent meningioma
Disease control Recruiting nowThe objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Phase: PHASE2 • Sponsor: Exelixis • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New cocktail aims to wipe out High-Risk prostate cancer before surgery
Disease control Recruiting nowThis is a single-arm, phase II study of neoadjuvant combination therapy of Androgen Deprivation Therapy (ADT), \[Gonadotropin-Releasing Hormone (GnRH) agonist Leuprolide\], androgen receptor (AR)-antagonist Darolutamide and Pembrolizumab in a stratified high-risk localized prosta…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for hard-to-treat leukemia: triple drug combo enters human testing
Disease control Recruiting nowThis phase I/Ib trial tests the safety and side effects of asparaginase Erwinia chrysanthemi-recombinant-rywn (recombinant Erwinia asparaginase) and venetoclax in combination with blinatumomab and how well the combination works in treating patients with CD19 positive B-cell acute…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC